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We summarized and compared meta-analyses of pharmacological and non-pharmacological interventions targeting physical health outcomes 
among people with schizophrenia spectrum disorders. Major databases were searched until June 1, 2018. Of 3,709 search engine hits, 27 meta-
analyses were included, representing 128 meta-analyzed trials and 47,231 study participants. While meta-analyses were generally of adequate 
or high quality, meta-analyzed studies were less so. The most effective weight reduction interventions were individual lifestyle counseling (stan-
dardized mean difference, SMD=–0.98) and exercise interventions (SMD=–0.96), followed by psychoeducation (SMD=–0.77), aripiprazole 
augmentation (SMD=–0.73), topiramate (SMD=–0.72), d-fenfluramine (SMD=–0.54) and metformin (SMD=–0.53). Regarding waist circum-
ference reduction, aripiprazole augmentation (SMD=–1.10) and topiramate (SMD=–0.69) demonstrated the best evidence, followed by dietary 
interventions (SMD=–0.39). Dietary interventions were the only to significantly improve (diastolic) blood pressure (SMD=–0.39). Switching 
from olanzapine to quetiapine or aripiprazole (SMD=–0.71) and metformin (SMD=–0.65) demonstrated best efficacy for reducing glucose 
levels, followed by glucagon-like peptide-1 receptor agonists (SMD=–0.39), dietary interventions (SMD=–0.37) and aripiprazole augmenta-
tion (SMD=–0.34), whereas insulin resistance improved the most with metformin (SMD=–0.75) and rosiglitazone (SMD=–0.44). Topiramate 
had the greatest efficacy for triglycerides (SMD=–0.68) and low-density lipoprotein (LDL)-cholesterol (SMD=–0.80), whereas metformin had 
the greatest beneficial effects on total cholesterol (SMD=–0.51) and high-density lipoprotein (HDL)-cholesterol (SMD=0.45). Lifestyle interven-
tions yielded small effects for triglycerides, total cholesterol and LDL-cholesterol (SMD=–0.35 to –0.37). Only exercise interventions increased 
exercise capacity (SMD=1.81). Despite frequent physical comorbidities and premature mortality mainly due to these increased physical health 
risks, the current evidence for pharmacological and non-pharmacological interventions in people with schizophrenia to prevent and treat these 
conditions is still limited and more larger trials are urgently needed.
Key words: Schizophrenia, psychosis, physical health, body weight, blood pressure, glucose, insulin, tryglicerides, cholesterol, lifestyle coun­
seling, exercise interventions, dietary interventions, metformin, topiramate, antipsychotic switching
(World Psychiatry 2019;18:53–66)
People with schizophrenia have substantially poorer physi­
cal health than the general population1­4, which is often attrib­
uted to an interaction between social circumstances, lifestyle 
factors and treatment effects5. For instance, behavioral re­
search has demonstrated that people with schizophrenia are 
less physically active and exhibit more sedentary behavior than 
the general population6, have a higher quantity but lower qual­
ity of dietary food intake7, and increased adverse health behav­
iors, such as smoking8. Additionally, psychiatric treatment with 
antipsychotics and other commonly prescribed agents, such 
as mood stabilizers and antidepressants, further increases the 
risk of physical health conditions9,10. Consequently, people 
with schizophrenia more frequently have cardio­metabolic 
diseases11­13, respiratory diseases14, chronic pain15, fractures16, 
and lower physical fitness17,18 than the general population.
This increased somatic risk is associated with a lower physi­
cal health related quality of life19,20, but, despite this increased 
risk, access to monitoring, physical health care and interven­
tion for those with schizophrenia are suboptimal compared 
to the general population21,22. Resultantly, people with schizo­
phrenia experience a 10­20 year gap in life expectancy, primar­
ily driven by this poorer physical health13,23. Furthermore, the 
physical health inequalities experienced by people with schizo­
phrenia have been observed across the globe24 and have not 
improved over time25.
Given this gross inequality, there has been a substantial 
increase in efforts to improve the physical health of this at­
risk population5,26. To address the physical health disparity, a 
number of individual meta­analyses have led to national and 
international evidence­based recommendations for or against 
specific pharmacological and non­pharmacological interven­
tion options27­34.
Despite this rapid expansion of meta­analytic evidence on 
interventions for tackling poor physical health in people with 
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schizophrenia, no summary of this top­tier of evidence exists, 
nor is there a direct quantitative comparison of the evidence 
between all individual and/or combined pharmacological and 
non­pharmacological strategies. Moreover, the quality of these 
meta­analyses and the included trials has not been comprehen­ 
sively evaluated, which is an indispensable step before more 
rigorous treatment recommendations can confidently be made.
In order to address this gap within the literature, we set out 
to aggregate the existing top­tier evidence from the most re­
cent/largest published meta­analyses of randomized trials of 
physical health interventions, in order to determine the com­
parative quality of evidence and magnitude of efficacy for phar­
macological and non­pharmacological interventions targeting 
physical health outcomes among people with schizophrenia 
spectrum disorders.
METHODS
Searches
Four authors searched independent from each other MED­
LINE/PubMed, PsycINFO, EMBASE and the Cochrane data­
bases, from their respective inception dates until June 1, 2018, 
without language restriction, for meta­analyses of randomized 
controlled trials in people with schizophrenia spectrum dis­
orders where physical health improvements were the primary 
outcome.
The search terms included (“meta­analysis” OR “system­
atic review”) AND (“random*” OR “placebo” OR “control*”) 
AND (“schizophrenia” OR “schizoaffective” OR “schizophreni­
form” OR “psychosis” OR “psychotic” OR “severe mental ill­
ness”) AND (“physical health” OR “cardio*” OR “metabol*” OR 
“respir*” OR “*weight” OR “pain” OR “somatic”). We searched 
the reference lists of all included articles.
Inclusion criteria
Inclusion criteria were organized in accordance with the pop­ 
ulation, interventions, comparisons, outcomes and setting/
study design (PICOS) reporting structure (see Table 1).
Data extraction, outcomes, and data synthesis
Regarding efficacy and adverse drug reactions, we manually 
extracted effect size data (with 95% confidence intervals, CI) for 
all relevant outcomes, and the number of participants in the 
intervention and control arms for each effect size. Specifically, 
data for effect sizes of continuous outcomes were extracted or 
recalculated as standardized mean difference (SMD), which 
expresses the mean difference between the intervention and 
control groups in standard deviation units, with 95% CI. Gen­
erally, an SMD less than 0.2 is considered negligible, an SMD 
between 0.2 and less than 0.5 is small, an SMD between 0.5 and 
less than 0.8 is medium, and an SMD of at least 0.8 is large35. 
Risk ratios (RRs) were used for categorical outcomes. If odds ra­
tios were present, they were recalculated as RRs. For both types 
of outcomes, we followed the decisions of the original authors 
concerning fixed vs. random effects models.
Quality assessment of the meta-analyzed studies
Included meta­analyses were assessed using “A Measure­
ment Tool to Assess Systematic Reviews” (AMSTAR) (range 
0­11, with a score of 8 or higher indicating high quality)36.
While AMSTAR is a reliable and valid tool for measuring the 
methodological quality of meta­analyses, its score does not 
capture quality indicators of the meta­analyzed trials, which 
Table 1 Application of  the PICOS search strategy
Population – People with schizophrenia spectrum disorders, including 
schizophrenia, schizoaffective or schizophreniform disorder or first  
episode psychosis, confirmed through validated assessment measures (e.g., 
DSM, ICD). Studies conducted with a severe mental illness subgroup 
(e.g., also including bipolar disorder or major depressive disorder) were  
only included if  the schizophrenia spectrum disorder sample was ≥70%.
Interventions – We included all pharmacological interventions that had a 
primary aim to improve physical health outcomes. Non-pharmacological 
interventions included all educational, psychotherapeutic, social and 
physical interventions, excluding alternative therapies. Specifically, we 
included lifestyle interventions (e.g., physical activity, diet, smoking  
cessation).
Comparisons – All relevant control interventions were included (e.g.,  
placebo, treatment as usual/usual care, waiting list, no treatment).
Outcomes – We considered any physical health outcomes explored, 
including the following: a) any physical health markers, such as body 
weight, proportion with overweight or obesity, random or fasting levels of  
glucose and lipid metabolism parameters, proportion with abnormalities 
in glucose and lipid metabolism parameters, cardiovascular illness (e.g., 
myocardial infarction, stroke, transient ischemic attack, pulmonary  
embolism), respiratory illness (lung cancer, chronic obstructive pulmonary 
disease); b) parameters of  physical fitness (e.g., maximal or peak oxygen  
uptake, muscle strength); c) any biomarkers investigated (hemoglobin 
A1c, C-reactive protein or other blood and serum markers); d) any  
physical health behavior researched (physical activity levels, smoking 
behavior, diet patterns, attending physical health appointment, attendance 
rates); e) physical health related quality of  life; f) side effects (e.g., adverse 
drug reactions).
Setting – We considered any setting: hospital (inpatient or outpatient),  
community, or remote (e.g., using digital technology).
Study design – Meta-analyses informed by a systematic review that included 
randomized controlled trials (RCTs) were included. A paper was  
classified as a systematic review and meta-analysis if  the following criteria 
were met: clear inclusion criteria, a systematic search strategy, a screening 
procedure to identify relevant studies, systematic data extraction and  
meta-analysis procedures for RCTs. Meta-analyses meeting the inclusion 
criteria were removed if  there was a more recently updated meta-analysis 
for that same combination strategy and outcome as long as more than 
75% of  the meta-analyzed trials overlapped and the pooled sample was 
larger for that specific intervention and outcome. Conference abstracts 
were excluded.
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could bias pooled results. For instance, a meta­analysis that 
meets all methodological quality criteria, but that meta­analyz­
es potentially biased studies would have a good methodologi­
cal quality but poor content quality.
Thus, for a more comprehensive assessment of the content 
validity of included meta­analyses, we used a set of six addition­
al, previously developed quality items, each ranging between 0 
and 1 or 2, that capture the content quality of the meta­analyzed 
trials (AMSTAR­Plus Content, range 0­8, with a score of 4 or 
higher indicating high quality)37.
Statistical analysis
We analyzed data as they were directly extracted from the 
pub lished meta­analyses or, if necessary, after they were con­
verted to standardized outcomes using comprehensive meta­
analysis (CMA, version 3) (Biostat). To compare the SMDs of the 
experimental pharmacological and non­pharmacological inter­
ventions vs. the control interventions, we conducted separate 
random­effects meta­analyses for each variable using CMA.
The AMSTAR and AMSTAR­Plus Content scores and sample 
size were used where possible in meta­regression analyses, 
which were done separately for pharmacological and non­
pharmacological strategies. Where possible, we also performed 
meta­regression and subgroup analyses to examine putative 
factors which may influence effect sizes for each individual 
physical health outcome, including participant characteristics 
(e.g., average age, gender distribution) and interventional de­
sign (treatment duration in weeks, delivered by mental health 
vs. physical health staff, clinical setting, percent of sessions at­
tended/adherence, group vs. individual treatment).
Heterogeneity was quantified using the Q and I2 statistic, 
with scores of <25%, 25­50% and >50% indicating low, moder­
ate and high heterogeneity, respectively38. If it was not possible 
to extract effect size data for the comparative meta­analysis, we 
reported individual review level results in a narrative synthesis.
RESULTS
Systematic search results
Of 3,709 search engine hits, 27 meta­analyses were includ­
ed39­65, representing a total of 128 meta­analyzed trials and 
47,231 study participants.
There were meta­analytic data for 17 different pharma­
cological interventions: aripiprazole augmentation43,47,53,55, 
fluoxetine55, metformin46,48,49,54,55,61,62, nizatidine54,55, NMDA 
receptor antagonists including amantadine and memantine 
45,55,57,60, ranitidine42, topiramate39, dextroamphetamine64, 
d­fenfluramine64, famotidine64, metformin in combination 
with sibutramine64, orlistat64, rosiglitazone64, fluvoxamine64, 
glucagon­like peptide­1 receptor agonists (GLP­1 RAs)40, and 
switching from olanzapine to quetiapine or aripiprazole65.
Meta­analytic data were available for six different non­phar­
macological interventions: individual lifestyle counseling58,59,63, 
group lifestyle counseling58,59,63, cognitive behavioral thera­
py58,59, psychoeducation58, exercise50,56,58, and dietary interven­
tions44,58. One meta­analysis investigated the pooled effect of a 
combined lifestyle and metformin intervention41.
In total, 17 different physical health outcomes were investi­
gated: weight, body mass index, waist circumference, waist to 
hip ratio, diastolic and systolic blood pressure, fasting glucose, 
insulin, homeostatic model assessment of insulin resistance, 
hemoglobin A1c, fasting triglycerides, total cholesterol, high­
density lipoprotein (HDL)­cholesterol, low­density lipoprotein 
(LDL)­cholesterol, android/gynoid ratio (i.e., percent fat ratio 
defined as android fat divided by gynoid fat), visceral fat, and 
functional exercise capacity.
The control interventions included placebo, continued psy­
chotropic treatment, or care as usual for pharmacological trials, 
and care as usual for non­pharmacological trials.
The number of trials for a specific health outcome ranged 
from one to 29, with a median of five trials (interquartile range = 
5). Trials lasted six to 72 weeks. When reported, the mean age of 
participants was 34.9±2.0 years, and 58.4% were men.
Quality assessment of the included meta-analyses
The AMSTAR mean score was 8.8±1.0 in the whole sample, 
8.9±0.9 in the pharmacological interventions, and 8.7±1.0 in the 
non­pharmacological interventions. Twenty­four (89%) meta­
analyzed studies had an AMSTAR score of 8 or higher, but only 
two42,65 (4%) had the maximum AMSTAR score of 11. The AM­
STAR­Plus Content mean score was 3.4±1.5 in the whole sample, 
3.2±1.6 in the pharmacological interventions, and 3.7±1.1 in the 
non­pharmacological interventions. None had the maximum 
score of 8.
Only eleven meta­analyses (41%) were rated as high­quality 
based on the meta­analyzed studies. Seven of the 27 meta­
analyses included only double­blind trials (26%). In 16 meta­
analyses (59%), the total pooled sample was less than 500 
cases, while only five meta­analyses (18%) had a total sample 
of more than 1,000 participants. Only two meta­analyses49,53 
(7%) had one included trial with at least 200 participants. 
 Finally, following the AMSTAR­Plus Content criteria, a signifi­
cant heterogeneity was found for 12 meta­analyses (44%), and 
18 (67%) could not disprove the presence of a publication bias.
Further, we examined the relationship between the effect 
size for both the non­pharmacological and pharmacological 
interventions versus the control conditions with the quality 
assessment measures (AMSTAR and AMSTAR­Plus Content). 
The SMDs for pharmacological and non­pharmacological 
 interventions did not correlate significantly with the meth­
odological quality of the meta­analysis as measured by AM­
STAR (p=0.37 to 0.52) nor with the content quality of the meta­ 
analysis as measured by AMSTAR­Plus Content (p=0.17 to 
0.97).
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Table 2 Anthropometric physical health outcomes of  pharmacological and non-pharmacological interventions in people with schizophrenia
Outcomes Intervention SMD 95% CI N. trials N. participants AMSTAR
AMSTAR 
Plus Content Effect size
Between-
group p
Weight reduction <0.001
Individual lifestyle 
counseling
–0.98*** –1.15 to –0.81 14 411 8.3 3.7 Large
Exercise 
 interventions
–0.96*** –1.27 to –0.66 4 183 8.0 2.5 Large
Psychoeducation –0.77*** –0.98 to –0.55 8 345 8.0 3.0 Medium
Aripiprazole 
 augmentation
–0.73*** –0.97 to –0.48 9 813 8.3 3.0 Medium
Topiramate –0.72*** –1.56 to –0.33 15 783 10.0 3.0 Medium
d-Fenfluramine –0.54*** –1.07 to –0.02 1 16 7.0 6.0 Medium
Metformin –0.53*** –0.69 to –0.38 29 1,279 8.2 3.6 Medium
Dietary interventions –0.50*** –0.66 to –0.34 22 1,576 8.5 3.5 Medium
NMDA receptor 
antagonists
–0.47*** –0.62 to –0.32 5 309 8.0 4.5 Small
Metformin + lifestyle 
intervention
–0.44*** –0.69 to –0.19 3 122 9.0 1.0 Small
GLP-1 RAs –0.44*** –0.60 to –0.28 3 168 9.0 1.0 Small
Group lifestyle 
 counseling
–0.39*** –0.54 to –0.23 19 883 8.3 3.7 Small
Amantadine –0.30* –0.57 to –0.03 3 205 8.5 3.5 Small
Cognitive behavioral 
therapy
–0.37* –0.55 to –0.18 11 546 8.3 3.7 Small
Nizatidine –0.12* –0.24 to 0.00 4 357 8.0 3.0 Negligible
Ranitidine –0.24 –0.67 to 0.20 4 260 11.0 1.0 Non-significant
Metformin + 
sibutramine
–0.24 –0.62 to 0.13 1 28 7.0 6.0 Non-significant
Orlistat –0.21 –0.46 to 0.04 1 63 7.0 6.0 Non-significant
Rosiglitazone 0.14 –0.21 to 0.52 1 29 7.0 6.0 Non-significant
Fluoxetine 0.14 –0.09 to 0.36 2 60 7.0 3.0 Non-significant
Dextroamphetamine 0.11 –0.33 to 0.56 1 20 7.0 6.0 Non-significant
Switching from 
olanzapine to 
quetiapine or 
aripiprazole
–0.11 –0.23 to 0.03 2 287 11.0 3.0 Non-significant
Famotidine –0.02 –0.48 to 0.43 1 14 7.0 6.0 Non-significant
Body mass index 
reduction
<0.001
Topiramate –0.56*** –1.54 to –0.22 11 449 10.0 3.0 Medium
Individual lifestyle 
counseling
–0.49*** –0.77 to –0.22 4 202 8.3 3.7 Small
GLP-1 RAs –0.41*** –0.57 to –0.26 3 168 9.0 1.0 Small
Cognitive  
behavioral therapy
–0.34* –0.67 to –0.07 6 308 8.0 3.7 Small
Group lifestyle 
 counseling
–0.28* –0.54 to 0.00 4 202 8.3 3.7 Small
Metformin –0.41 –0.93 to 0.10 23 1,228 9.0 3.7 Non-significant
Exercise  interventions –0.25 –0.56 to 0.06 8 231 8.0 2.5 Non-significant
Ranitidine –0.23 –0.44 to 0.00 5 312 11.0 1.0 Non-significant
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Physical health outcomes of pharmacological and  
non-pharmacological interventions
An overview of the different physical health outcomes of phar­
macological and non­pharmacological interventions in people 
with schizophrenia based on the SMDs and the quality of the 
meta­analyzed studies as assessed by the AMSTAR and AMSTAR­
Plus scores is presented in Table 2 (anthropometric results) and 
Table 3 (blood pressure, metabolic and exercise capacity results).
Body weight
Non-pharmacological interventions
Six meta­analyses investigated non­pharmacological inter­
ventions for body weight (78 trials, N=3,944). The mean AM­
STAR score was 8.2±0.2 and the mean AMSTAR­Plus Content 
was 3.3±0.4.
Individual lifestyle counseling was the most effective inter­
vention (SMD=–0.98, 95% CI: –1.15 to –0.81, p<0.001; 14 trials, 
N=411, I2=0%, Q=0.5, i.e., large effect), followed by exercise in­
terventions alone (SMD=–0.96, 95% CI: –1.27 to –0.66, p<0.001; 
4 trials, N=183, I2=0, Q=0, i.e., large effect).
Psychoeducation interventions focusing on promoting a 
healthy lifestyle showed a medium effect (SMD=–0.77, 95% 
CI: –0.98 to –0.55, p<0.001; 8 trials, N=345, I2=0, Q=0). This was 
also the case for dietary interventions alone (SMD=–0.50, 95% 
CI: –0.66 to –0.34, p<0.001; 22 trials, N=1,576, I2=94%, Q=15.8).
A small effect was observed for cognitive behavioral therapy 
focusing on promoting a healthy lifestyle (SMD=–0.37, 95% 
CI: –0.55 to –0.18, p=0.022; 11 trials, N=546, I2=0%, Q=0.2) and 
group lifestyle counseling (SMD=–0.39, 95% CI: –0.54 to –0.23, 
p<0.001; 19 trials, N=883, I2=28%, Q=2.8).
With regards to prevention of weight increase, multidiscipli­
nary lifestyle/behavioral counseling showed a medium effect 
(SMD=–0.69, 95% CI: –0.84 to –0.54, p<0.001; 14 trials, N=694, 
I2=0%, Q=1.4).
Table 2 Anthropometric physical health outcomes of  pharmacological and non-pharmacological interventions in people with schizophrenia 
(continued)
Outcomes Intervention SMD 95% CI N. trials N. participants AMSTAR
AMSTAR 
Plus Content Effect size
Between-
group p
Switching from 
olanzapine to 
quetiapine
–0.12 –0.29 to 0.05 1 129 11.0 3.0 Non-significant
Waist  
circumference 
reduction
<0.001
Aripiprazole  
augmentation
–1.10** –1.42 to –0.79 3 174 10.0 2.0 Large
Topiramate –0.69* –0.93 to –0.45 8 310 10.0 3.0 Medium
Dietary  
interventions
–0.39*** –0.56 to –0.22 11 858 8.5 3.5 Small
Lifestyle  
interventions
–0.37** –0.60 to –0.13 10 705 8.0 5.0 Small
GLP-1 RAs –0.34*** –0.50 to –0.18 3 167 9.0 1.0 Small
Metformin –0.01 –0.68 to 0.65 12 721 9.0 6.0 Non-significant
Waist to hip ratio 
reduction
0.07
Topiramate –0.69** –0.90 to 0.27 5 123 10.0 3.0 Medium
Metformin –0.32 –1.15 to 0.51 3 133 8.0 5.0 Non-significant
GLP-1 RAs 0.03 –0.13 to 0.18 3 163 9.0 1.0 Non-significant
Android/gynoid 
ratio
GLP-1 RAs –0.03 –0.20 to 0.13 3 131 9.0 1.0 Non-significant
Visceral fat  
reduction
GLP-1 RAs –0.37* –0.46 to –0.06 3 97 9.0 1.0 Small
*p<0.05, **p<0.01, ***p<0.001
SMD – standardized mean difference, GLP-1 RAs – glucagon-like peptide-1 receptor agonists, AMSTAR – A Measurement Tool to Assess Systematic Reviews 
mean scores
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Table 3 Blood pressure, metabolic and exercise capacity physical health outcomes of  pharmacological and non-pharmacological interventions 
in people with schizophrenia
Outcomes Intervention SMD 95% CI N. trials N. participants AMSTAR
AMSTAR 
Plus Content Effect size
Between-
group p
Systolic blood  
pressure  
reduction
0.14
Metformin –0.24 –0.53 to 0.05 3 176 9.0 4.0 Non-significant
Lifestyle interventions –0.22 –0.49 to 0.05 7 615 8.0 5.0 Non-significant
GLP-1 RAs –0.09 –0.24 to 0.06 3 160 9.0 1.0 Non-significant
Dietary interventions 0.05 –0.18 to 0.28 7 655 8.5 3.5 Non-significant
Diastolic blood 
pressure  
reduction
<0.001
Dietary interventions –0.39** –0.56 to –0.22 6 654 8.5 3.5 Small
Metformin –0.24 –0.53 to 0.05 3 176 9.0 4.0 Non-significant
GLP-1 RAs –0.12 –0.28 to 0.03 3 160 9.0 1.0 Non-significant
Lifestyle interventions –0.08 –0.57 to 0.41 3 171 8.0 5.0 Non-significant
Glucose level 
reduction
<0.001
Switching from 
olanzapine to 
quetiapine or 
aripiprazole
–0.71*** –0.85 to –0.58 2 280 11.0 3.0 Medium
Metformin –0.65*** –0.94 to –0.35 17 1,281 9.6 3.7 Medium
GLP-1 RAs –0.39*** –0.54 to –0.23 3 166 9.0 1.0 Small
Dietary interventions –0.37* –0.69 to –0.05 6 422 8.5 3.5 Small
Aripiprazole  
augmentation
–0.34*** –0.47 to –0.20 10 710 9.3 3.5 Small
Topiramate –0.43 –1.00 to 0.14 6 369 10.0 3.0 Non-significant
Lifestyle interventions –0.27 –0.59 to 0.05 8 688 8.0 5.0 Non-significant
Insulin level  
reduction
<0.001
Rosiglitazone –0.42* –0.80 to 0.00 1 29 7.0 6.0 Small
Lifestyle interventions –0.28* –0.55 to 0.00 6 481 8.0 5.0 Small
Metformin –0.37 –0.81 to 0.07 15 1,007 9.5 4.5 Non-significant
Dietary interventions –0.19 –0.42 to 0.04 11 787 8.5 3.5 Non-significant
HOMA-IR 
improvement
<0.001
Metformin –0.75*** –1.10 to –0.40 11 680 9.0 6.0 Medium
Rosiglitazone –0.44* –0.82 to –0.06 1 29 7.0 6.0 Small
GLP-1 RAs –0.08 –0.23 to 0.08 3 163 9.0 1.0 Non-significant
HbA1c reduction
Metformin –0.38* –0.69 to -0.07 4 383 9.0 6.0 Small
GLP-1 RAs –0.38* –0.53 to –0.22 3 166 9.0 1.0 Small
Triglycerides 
reduction
<0.001
Topiramate –0.68* –1.23 to –0.13 5 268 10.0 3.0 Medium
Lifestyle interventions –0.37*** –0.54 to –0.20 8 659 8.0 5.0 Small
Metformin –0.28*** –0.45 to –0.11 11 856 9.0 4.0 Small
World Psychiatry 18:1 - February 2019 59
Pharmacological interventions
Altogether, 14 meta­analyses investigated pharmacological 
interventions for body weight (82 trials, N=4,691). The mean 
AMSTAR score was 8.1±1.3 and the mean AMSTAR­Plus Con­
tent was 4.0±1.7.
A medium effect size was observed for aripiprazole aug­
mentation (SMD=–0.73, 95% CI: –0.97 to –0.48, p<0.001; 9 tri­
als, N=813, I2=68%, Q=6.2), topiramate (SMD=–0.72, 95% CI: 
–1.56 to –0.33, p<0.001; 15 trials, N=783, I2=92.7%, Q=13.7), 
d­fenfluramine (SMD=–0.54, 95% CI: –1.07 to –0.02, p<0.001; 
one trial, N=16) and metformin (SMD=–0.53, 95% CI: –0.69 to 
–0.38, p<0.001; 29 trials, N=1,279, I2=39.4%, Q=1.6).
A small significant effect was shown by NMDA receptor an­
tagonists (SMD=–0.47, 95% CI: –0.62 to –0.32, p<0.001; 5 trials, 
N=309, I2=0%, Q=0.1), GLP­1 RAs (SMD=–0.44, 95% CI: –0.60 to 
–0.28, p<0.001; 3 trials, N=168, I2=0%, Q=0.1) and amantadine 
(SMD=–0.30, 95% CI: –0.57 to –0.03, p=0.03; 3 trials, N=205, 
I2=0%, Q=0). Nizatidine showed a negligible effect (SMD=–0.12, 
95% CI: –0.24 to 0.00, p=0.02; 4 trials, N=357, I2=0%, Q=0.4).
No significant weight loss compared to the control condi­
tion was observed for fluoxetine (SMD=0.14, 95% CI: –0.09 
Table 3 Blood pressure, metabolic and exercise capacity physical health outcomes of  pharmacological and non-pharmacological interventions 
in people with schizophrenia (continued)
Outcomes Intervention SMD 95% CI N. trials N. participants AMSTAR
AMSTAR 
Plus Content Effect size
Between-
group p
Aripiprazole  
augmentation
–0.17** –0.30 to –0.04 9 631 9.5 3.5 Negligible
GLP-1 RAs –0.15* –0.31 to –0.02 3 166 9.0 1.0 Negligible
Dietary interventions –0.15 –0.30 to 0.00 7 611 8.5 3.5 Non-significant
Total cholesterol 
reduction
0.02
Metformin –0.51*** –0.81 to –0.20 8 628 9.0 6.0 Medium
Lifestyle interventions –0.35** –0.54 to –0.16 7 590 8.0 5.0 Small
Aripiprazole  
augmentation
–0.32*** –0.47 to –0.17 10 692 9.3 3.5 Small
Topiramate –0.75 –1.57 to 0.07 3 187 10.0 3.0 Non-significant
Dietary interventions –0.13 –0.29 to 0.03 7 621 8.5 3.5 Non-significant
HDL-cholesterol 
elevation
0.007
Metformin 0.45* 0.00 to 0.90 7 542 9.0 6.0 Small
Lifestyle interventions 0.28 –0.16 to 0.72 8 627 8.0 5.0 Non-significant
GLP-1 RAs –0.04 –0.19 to 0.11 3 166 9.0 1.0 Non-significant
Topiramate –0.07 –0.57 to 0.43 4 247 10.0 3.0 Non-significant
Dietary interventions –0.09 –0.24 to 0.06 7 547 8.5 3.5 Non-significant
Aripiprazole  
augmentation
–0.27 –0.44 to 0.01 8 544 9.3 3.5 Non-significant
LDL-cholesterol 
reduction
<0.001
Topiramate –0.80*** –1.06 to –0.53 4 247 10.0 3.0 Large
Lifestyle interventions –0.36** –0.60 to –0.12 5 590 8.0 5.0 Small
GLP-1 RAs –0.17* –0.32 to –0.02 3 162 9.0 1.0 Negligible
Metformin –0.11 –0.31 to 0.09 5 433 9.0 6.0 Non-significant
Aripiprazole  
augmentation
–0.01 –0.18 to 0.15 8 540 9.3 3.5 Non-significant
Functional  
exercise capacity
Exercise interventions 1.81** 0.59 to 3.03 1 13 8.0 2.0 Large
*p<0.05, **p<0.01, ***p<0.001
SMD – standardized mean difference, GLP-1 RAs – glucagon-like peptide-1 receptor agonists, AMSTAR – A Measurement Tool to Assess Systematic Reviews mean 
scores, HbA1c – hemoglobin A1c, HOMA-IR – homeostatic model assessment of  insulin resistance, HDL – high-density lipoprotein, LDL – low-density lipoprotein
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to 0.36, p=0.22; 2 trials, N=60, I2=0%, Q=0), dextroampheta­
mine (SMD=0.11, 95% CI: –0.33 to 0.56, p=0.60; one trial, 
N=20), ranitidine (SMD=–0.24, 95% CI: –0.67 to 0.20, p=0.05; 
4 trials, N=260), famotidine (SMD=–0.02, 95% CI: –0.48 to 0.43, 
p=0.91; one trial, N=14), the combination of metformin with 
sibutramine (SMD=–0.24, 95% CI: –0.62 to 0.13, p=0.19; one tri­
al, N=28), orlistat (SMD=–0.21, 95% CI: –0.46 to 0.04, p=0.09; one 
trial, N=63) and rosiglitazone (SMD=0.14, 95% CI: –0.21 to 0.52, 
p=0.19; one trial, N=29). Switching from olanzapine to que­
tiapine or aripiprazole fell also short of statistical significance 
(SMD=–0.11, 95% CI: –0.23 to 0.03, p=0.06; 2 trials, N=287).
Combined pharmacological and non-pharmacological 
interventions
The combination of metformin with a lifestyle intervention 
was explored in one meta­analysis and demonstrated a small 
effect (SMD=–0.44, 95% CI: –0.69 to –0.19, p<0.001; 3 trials, 
N=122, I2=0, Q=0).
Body mass index
Non-pharmacological interventions
Four meta­analyses investigated non­pharmacological in­
terventions for body mass index (42 trials, N=2,157). The mean 
AMSTAR score was 9.7±0.8 and the mean AMSTAR­Plus Con­
tent was 2.2±1.2.
A small effect was observed for group lifestyle counseling 
(SMD=–0.28, 95% CI: –0.54 to 0.00, p=0.04; 4 trials, N=202, 
I2=0%, Q=0), individual lifestyle counseling (SMD=–0.49, 95% 
CI: –0.77 to –0.22, p<0.001; 4 trials, N=202, I2=0%, Q=0), and 
cognitive behavioral therapy focusing on promoting healthy 
lifestyles (SMD=–0.34, 95% CI: –0.67 to –0.07, p=0.02; 6 trials, 
N=308, I2=0%, Q=0.2).
No significant reduction in body mass index compared to 
the control condition was observed for exercise interventions 
(SMD=–0.25, 95% CI: –0.56 to 0.06, p=0.11; 8 trials, N=231, I2 
=0%, Q=0.4).
Pharmacological interventions
Six meta­analyses investigated pharmacological interven­
tions for body mass index (81 trials, N=4,533). The mean AM­
STAR score was 8.1±1.3 and the mean AMSTAR­Plus Content 
was 4.0±1.9.
Topiramate (SMD=–0.56, 95% CI: –1.54 to –0.22, p<0.001; 11 
trials, N=449, I2=0%, Q=0) had a medium reducing effect, while 
GLP­1 RAs demonstrated a small effect (SMD=–0.41, 95% CI: 
–0.57 to –0.26, p<0.001; 3 trials, N=168, I2=0%, Q=0).
No reduction of body mass index was observed with met­
formin (SMD=–0.41, 95% CI: –0.93 to 0.10, p=0.10; 23 trials, 
N=1,228, I2=90%, Q=20.0), ranitidine (SMD=–0.23, 95% CI: 
–0.44 to 0.00, p=0.55; 5 trials, N=312, I2=0%, Q=0), and switch­
ing from olanzapine to quetiapine (SMD=–0.12, 95% CI: –0.29 
to 0.05, p=0.16; one trial, N=129).
Waist circumference
Non-pharmacological interventions
Three meta­analyses investigated non­pharmacological in­
terventions for waist circumference reduction (24 trials, N= 
1,709). The mean AMSTAR score was 9.3±0.5 and the mean 
AMSTAR­Plus Content was 4.0±0.8.
A small waist circumference reduction effect compared to 
care as usual was observed for dietary interventions (SMD=–0.39, 
95% CI: –0.56 to –0.22, p<0.001; 11 trials, N=858, I2=0%, Q=0) and 
multidisciplinary lifestyle/behavioral interventions (SMD=–0.37, 
95% CI: –0.60 to ­0.13, p=0.002; 10 trials, N=705, I2=0%, Q=0).
Pharmacological interventions
Seven meta­analyses investigated pharmacological inter­
ventions for waist circumference reduction (32 trials, N=1,755). 
The mean AMSTAR score was 9.3±0.7 and the mean AMSTAR­
Plus Content was 2.8±1.6.
Compared with the control condition, the most effective 
intervention was aripiprazole augmentation (SMD=–1.10, 95% 
CI: –1.42 to –0.79, p=0.001; 3 trials, N=174, I2=0%, Q=0, i.e., large 
effect).
Topiramate had a medium effect (SMD=–0.69, 95% CI: –0.93 
to –0.45, p<0.05; 8 trials, N=310, I2=0%, Q=0). GLP­1 RAs had 
a small effect (SMD=–0.34, 95% CI: –0.50 to –0.18, p<0.001; 3 
trials, N=167, I2=0%, Q=0). No significant waist circumference 
re duction compared to the placebo control condition was ob­
served for metformin (SMD=–0.01, 95% CI: –0.68 to 0.65, p=0.97; 
12 trials, N=721, I2=82%, Q=17.1).
Waist to hip ratio
Three meta­analyses investigated the effects of pharmaco­
logical interventions on the waist to hip ratio (11 trials, N=419). 
The mean AMSTAR score was 9.3±0.5 and the mean AMSTAR­
Plus Content was 3.3±2.0.
A small waist to hip ratio reduction compared to the control 
condition was observed for topiramate (SMD=–0.69, 95% CI: 
–0.90 to 0.27, p=0.009; 5 trials, N=123, I2=0%, Q=0) and metformin 
(SMD=–0.32, 95% CI: –1.15 to 0.51, p=0.29; 3 trials, N=133, I2=0%, 
Q=0). GLP­1 RAs demonstrated no significant effect (SMD=0.03, 
95% CI: –0.13 to 0.18, p=0.39; 3 trials, N=163, I2=0%, Q=0).
Android/gynoid ratio
Based on data from one meta­analysis, GLP­1 RAs did not 
outperform the control condition concerning the effect on an­
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droid/gynoid ratio (SMD=–0.03, 95% CI: –0.20 to 0.13, p=0.46; 
3 trials, N=131, I2=0%, Q=0).
Visceral fat
Based on data from one meta­analysis, GLP­1 RAs had a 
small effect in reducing visceral fat (SMD=–0.37, 95% CI: –0.46 
to –0.06, p=0.02; 3 trials, N=97, I2=0%, Q=0).
Blood pressure
Non-pharmacological interventions
Four meta­analyses investigated non­pharmacological in­
terventions for blood pressure reduction (23 trials, N=2,095). 
The mean AMSTAR score was 9.0±0.0 and the mean AMSTAR­
Plus Content was 4.5±0.5.
When looking at dietary interventions alone, a small reduc­
tion in diastolic blood pressure versus care as usual was observed 
(SMD=–0.39, 95% CI: –0.56 to –0.22, p<0.01; 6 trials, N=654, 
I2=0, Q=0).
Compared to care as usual, no significant reduction in sys­
tolic (SMD=–0.22, 95% CI: –0.49 to 0.05, p=0.11; 7 trials, N=615, 
I2=0, Q=0) and diastolic blood pressure (SMD=–0.08, 95% CI: 
–0.57 to 0.41, p=0.74; 3 trials, N=171, I2=0, Q=0) was observed 
for multidisciplinary lifestyle/behavioral interventions.
Pharmacological interventions
Two meta­analyses investigated pharmacological interven­
tions for blood pressure (6 trials, N=336). The mean AMSTAR score 
was 9.5±0.5 and the mean AMSTAR­Plus Content was 1.5±0.5.
Compared to the placebo condition, no significant reduc­
tion in systolic and diastolic blood pressure was observed for 
metformin and GLP­1 RAs.
Glucose
Non-pharmacological interventions
Three meta­analyses investigated non­pharmacological in­
terventions on fasting glucose levels (16 trials, N=1,256). The 
mean AMSTAR score was 9.3±0.5 and the mean AMSTAR­Plus 
Content was 4.0±0.8.
Dietary interventions showed a small glucose level reduc­
ing effect (SMD=–0.37, 95% CI: –0.69 to –0.05, p=0.03; 6 trials, 
N=422, I2=0%, Q=0).
No significant reduction in glucose levels compared to care 
as usual was observed for multidisciplinary lifestyle/behavioral 
interventions (SMD=–0.27, 95% CI: –0.59 to 0.05, p=0.10; 8 tri­
als, N=688, I2=0%, Q=0).
Pharmacological interventions
Seven meta­analyses investigated the effect of pharmacolog­
ical interventions on fasting glucose levels (54 trials, N=3,617). 
The mean AMSTAR score was 9.6±0.6 and the mean AMSTAR­
Plus Content was 3.1±1.9.
A medium fasting glucose level lowering effect was found 
for switching olanzapine to quetiapine or aripiprazole (SMD= 
–0.71, 95% CI: –0.85 to –0.58, p<0.001; 2 trials, N=280), and for 
metformin (SMD=–0.65, 95% CI: –0.94 to –0.35, p<0.001; 17 tri­
als, N=1281, I2=0%, Q=0).
The effect was small for aripiprazole augmentation (SMD= 
–0.34, 95% CI: –0.47 to –0.21, p<0.001; 10 trials, N=710, I2=0%, 
Q=0) and GLP­1 RAs (SMD=–0.39, 95% CI: –0.54 to –0.23, p< 
0.001; 3 trials, N=166, I2=0%, Q=0).
No significant reduction in glucose levels compared to the 
placebo condition was observed for topiramate (SMD=–0.43, 
95% CI: –1.00 to 0.14, p=0.14; 6 trials, N=369, I2=0%, Q=0).
Insulin
Non-pharmacological interventions
Two meta­analyses investigated the effect of non­pharma­
cological interventions on insulin levels (9 trials, N=1,268). The 
mean AMSTAR score was 9.0±0.0 and the mean AMSTAR­Plus 
Content was 4.5±0.7.
Multidisciplinary lifestyle/behavioral interventions had a 
small effect in improving insulin sensitivity (SMD=–0.28, 95% 
CI: –0.55 to 0.00, p=0.04; 6 trials, N=481, I2=0%, Q=0). Dietary 
interventions alone did not outperform the control condition 
(SMD=–0.19, 95% CI: –0.42 to 0.04, p=0.10; 11 trials, N=787, 
I2=0%, Q=0).
Pharmacological interventions
Five meta­analyses investigated the impact of pharmaco­
logical interventions on insulin levels (23 trials, N=1,479). The 
mean AMSTAR score was 8.4±1.2 and the mean AMSTAR­Plus 
Content was 4.2±2.2.
Rosiglitazone had a small effect (SMD=–0.42, 95% CI: –0.80 
to 0.00, p=0.03; one trial, N=29). Metformin did not outper­
form the control condition (SMD=–0.37, 95% CI: –0.81 to 0.07, 
p=0.10; 15 trials, N=1007, I2=79.2%, Q=4.8).
Homeostatic model assessment of insulin resistance
Pharmacological interventions
Five meta­analyses investigated the effect of pharmacologi­
cal interventions on homeostatic model assessment of insulin 
resistance (19 trials, N=1,158). The mean AMSTAR score was 
8.4±1.2 and the mean AMSTAR­Plus Content was 4.2±2.2.
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Metformin (SMD=–0.75; 95% CI: –1.10 to –0.40, p<0.001; 11 
trials, N=680, I2=0%, Q=0, i.e., medium effect) and rosiglitazone 
(SMD=–0.44; 95% CI: –0.82 to –0.06, p=0.02; one trial, N=29, i.e., 
small effect) significantly outperformed the control condition, 
while GLP­1 RAs did not (SMD=–0.08; 95% CI: –0.23 to 0.08, 
p=0.10; 3 trials, N=163, I2=0%, Q=0).
Hemoglobin A1c
Two meta­analyses investigated pharmacological interven tions 
on hemoglobin A1c (7 trials, N=549). The mean AMSTAR score 
was 9.0±0.0 and the mean AMSTAR­Plus Content was 3.5±3.5.
Metformin (SMD=–0.38; 95% CI: –0.69 to –0.07, p=0.016; 4 
trials, N=383, I2=0%, Q=0) and GLP­1 RAs (SMD=–0.38; 95% 
CI: –0.53 to –0.22, p=0.02; 3 trials, N=166, I2=0%, Q=0) outper­
formed the placebo condition and showed a small effect.
Triglycerides
Non-pharmacological interventions
Four meta­analyses investigated the impact of non­pharma­
cological interventions on triglycerides (22 trials, N=1,671). The 
mean AMSTAR score was 8.7±1.1 and the mean AMSTAR­Plus 
Content was 4.2±0.8.
Multidisciplinary lifestyle/behavioral interventions had a 
small effect compared with care as usual (SMD=–0.37, 95% CI: 
–0.54 to –0.20, p<0.001; 8 trials, N=659, I2=40.0%, Q=1.7).  Die­
tary interventions did not outperform care as usual (SMD= 
–0.15; 95% CI: –0.30 to 0.00, p=0.06; 7 trials, N=611, I2=0%, Q=0).
Pharmacological interventions
Seven meta­analyses investigated the effect of pharmaco­
logical interventions on triglycerides (36 trials, N=2,564). The 
mean AMSTAR score was 9.1±1.0 and the mean AMSTAR­Plus 
Content was 3.6±1.9.
The effect compared with control condition was medium for 
topiramate (SMD=–0.68, 95% CI: –1.23 to –0.13, p=0.016; 5 tri­
als, N=268, I2=0%, Q=0), small for metformin (SMD=–0.28, 95% 
CI: –0.45 to –0.11, p<0.001; 11 trials, N=856, I2=5%, Q=2.1), and 
negligible for aripiprazole augmentation (SMD=–0.17, 95% CI: 
–0.30 to –0.04, p=0.009; 9 trials, N=631, I2=0%, Q=0) and GLP­1 
RAs (SMD=–0.15, 95% CI: –0.31 to –0.02, p=0.04; 3 trials, N=166, 
I2=0%, Q=0).
Cholesterol
Non-pharmacological interventions
Ten meta­analyses investigated non­pharmacological inter­
ventions for cholesterol levels (56 trials, N=4,288). The mean 
AMSTAR score was 8.5±1.0 and the mean AMSTAR­Plus Con­
tent was 4.5±0.7.
Regarding total cholesterol, multidisciplinary lifestyle/behav­
ioral interventions had a small benefit (SMD=–0.35, 95% CI: –0.54 
to –0.16, p=0.003; 7 trials, N=590, I2=0%, Q=0.3), while dietary in­
terventions alone did not outperform care as usual (SMD=–0.13; 
95% CI: –0.29 to 0.03, p=0.10; 7 trials, N=621, I2=0%, Q=0).
Regarding LDL­cholesterol, multidisciplinary lifestyle/be­
havioral interventions showed a small benefit (SMD=–0.36, 
95% CI: –0.60 to –0.12, p=0.003; 5 trials, N=590, I2=0%, Q=0.2).
No significant effects on HDL­cholesterol elevations were 
found with lifestyle or dietary interventions.
Pharmacological interventions
Fifteen meta­analyses investigated pharmacological inter­
ventions for cholesterol levels (74 trials, N=5,295). The mean 
AMSTAR score was 9.4±0.8 and the mean AMSTAR­Plus Con­
tent was 3.3±1.8.
Regarding total cholesterol, metformin (SMD=–0.51, 95% 
CI: –0.81 to –0.20, p<0.001; 8 trials, N=628, I2=0%, Q=0) dem­
onstrated a medium effect, while aripiprazole augmentation 
had a small effect (SMD=–0.32, 95% CI=–0.47 to –0.17, p<0.001; 
10 trials, N=692, I2=0%, Q=0). No significant reduction com­
pared to the control condition was observed for topiramate 
(SMD=–0.75, 95% CI: –1.57 to 0.07, p=0.07; 3 trials, N=187, I2=0%, 
Q=0).
Regarding LDL­cholesterol, topiramate (SMD=–0.80, 95% 
CI: –1.06 to –0.53, p<0.001; 4 trials, N=247, I2=0%, Q=0) and 
GLP­1 RAs (SMD=–0.17, 95% CI: –0.32 to –0.02, p=0.04; 3 tri­
als, N=162, I2=0%, Q=0) outperformed the control condition, 
although for the latter the effect was negligible. No signifi­
cant reductions compared to the control condition were found 
for aripiprazole augmentation (SMD=–0.01, 95% CI: –0.18 to 
0.15, p=0.88; 8 trials, N=540, I2=0%, Q=0) and for metformin 
(SMD=–0.11, 95% CI: –0.31 to 0.09, p=0.29; 5 trials, N=433, I2 
=0%, Q=0.2).
Regarding HDL­cholesterol, only metformin had a small ef­
fect (SMD=0.45, 95% CI: 0.00 to 0.90, p=0.049; 7 trials, N=542, 
I2=0%, Q=0), while aripiprazole augmentation, topiramate and 
GLP­1 RAs did not differ from the control condition.
Functional exercise capacity
Based on data from one meta­analysis, exercise outperformed 
the treatment as usual condition (SMD=1.81; 95% CI: 0.59 to 
3.03, p=0.004; one trial, N=13, I2=0%, Q=0, i.e., large effect).
Adverse drug reactions
Compared to placebo, aripiprazole had higher rates of anxi­
ety (number needed to harm, NNH=8, 95% CI: 5 to 20, p< 
0.001)47 and agitation/akathisia (RR=7.59, 95% CI: 1.43 to 40.18, 
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p=0.02)53. Amantadine was associated with higher rates of in­
somnia (RR=3.83, 95% CI: 1.41 to 10.38, p=0.008, NNH=9)57 
and abdominal discomfort (quantitative data not provided)60. 
GLP­1 RAs were associated with higher rates of nausea (NNH= 
3.8, 95% CI: 2.4 to 9.7, p<0.05)40. Among H2 antagonists, famoti­
dine and ranitidine were not associated with higher rates of ad­
verse reactions, while nizatidine had higher rates of dry mouth 
(RR=4.89, p=0.04; NNH=17, p=0.03) and depression (RR=5.00, 
p=0.03; NNH=17, p=0.02)52.
Of the six included meta­analyses of metformin, five report­
ed no difference in rates of adverse reactions41,46,48,54,62, while 
one reported higher rates of nausea/vomiting (NNH=16, 95% 
CI: 10 to 50, p=0.01) and diarrhoea (NNH=6, 95% CI: 3 to 25, p= 
0.01)49. Although there was no difference in rates of dropouts 
for orlistat, diarrhoea was the main reason for discontinuation 
of this drug48.
Sibutramine plus metformin were associated with an in­
crease of psychotic symptoms. Topiramate was associated 
with a higher rate of paraesthesia (RR=2.31, 95% CI: 1.17 to 
4.56, p<0.05)39. There were no data for dextroamphetamine, 
d­fenfluramine and rosiglitazone. Antipsychotic switching 
(olanzapine to quetiapine) was associated with higher rates of 
psychiatric adverse events54.
None of the meta­analyses reported on adverse effects of 
non­pharmacological interventions.
Meta-regression analyses
Due to limited data, no meta­regression or subgroup analy­
sis could be performed to examine whether duration of treat­
ment or illness, delivery of the intervention by mental health 
vs. physical health staff, clinical setting, percent of sessions 
attended or adherence to treatment could explain variance in 
the outcomes of interventions.
Study level variance in age and gender did not explain the 
variance in weight, body mass index or triglycerides levels 
following pharmacological or non­pharmacological interven­
tions.
DISCUSSION
To our knowledge, this meta­review of meta­analyses is the 
first to systematically and quantitatively compare the pharmaco­
logical and non­pharmacological interventions that have been 
investigated for improving physical health outcomes in people 
with schizophrenia. Our data shed new light on the areas where 
there is or there is not evidence to improve physical health in 
these people, and should help guide clinical practice and indi­
cate where future research priorities should focus.
When looking at non­pharmacological treatments, individ­
ual lifestyle counseling showed a large weight reducing effect. 
For dietary interventions, the weight reducing effect size was 
medium, and diastolic blood pressure and glucose level low­
ering effects were small. Exercise demonstrated large weight 
reducing effects and large effects on functional exercise ca­
pacity, although the evidence for the latter was limited to one 
small study.
The characteristics of the lifestyle interventions were exam­
ined to provide guidelines for future clinical practice. One key 
finding was that individualized lifestyle interventions showed 
large effects for reducing body weight, while only a small ef­
fect was observed for group­based approaches. Apparently, 
the benefits of an individual strategy, such as personal advice 
and attention, meeting patient­specific needs, and a tailored 
action plan, surpasses the benefits of group­based sessions, 
such as interpersonal learning, imitative behavior, recogni­
tion of similarities in other group members, group cohesive­
ness and peer support66. Future research should, however, 
explore whether a combined approach, encompassing group 
sessions while addressing patient­specific needs with a tai­
lored action plan, would be most efficacious.
Cognitive behavioral interventions focusing on weight loss 
and psychoeducation demonstrated, respectively, small and 
medium weight reducing effects.
Across 17 pharmacological strategies, 12 outperformed the 
control condition on various physical health outcomes. No 
beneficial effects were found for fluoxetine, ranitidine, orlistat, 
dextroamphetamine and famotidine for any physical health 
outcome.
Topiramate showed a large effect on LDL­cholesterol, and 
a medium effect on weight, body mass index, waist circumfer­
ence and triglycerides. Metformin demonstrated a medium 
effect on weight, total cholesterol, fasting glucose levels, and 
homeostatic model assessment of insulin resistance; and a 
small effect on hemoglobin A1c, triglycerides, and HDL­cho­
lesterol.
Switching from olanzapine to quetiapine or aripiprazole 
showed a medium fasting glucose lowering effect, while the ef­
fect of aripiprazole augmentation on this parameter was small. 
Aripiprazole augmentation also had a large effect on waist cir­
cumference and a medium effect on body weight.
A small weight reducing effect was found for NMDA recep­
tor antagonists. GLP­1 RAs showed small effects on waist cir­
cumference, glucose and hemoglobin A1c. Rosiglitazone had 
a small improving effect on homeostatic model assessment of 
insulin resistance. Finally, negligible effects were observed for 
aripiprazole augmentation and GLP­1 RAs on triglycerides, and 
for GLP­1 RAs on LDL­cholesterol.
In summary, based on the SMDs and the overall high meth­
odological quality of the original meta­analyses (but with lower 
quality of the meta­analyzed content), individual lifestyle coun­
seling and exercise interventions showed the largest weight 
reducing effect, followed by psychoeducation, aripiprazole 
augmentation, topiramate, di­fenfluramine and metformin. 
With regard to waist circumference, aripiprazole augmentation 
and topiramate demonstrated the best impact, followed by die­
tary interventions. Dietary interventions were the only to sig­
nificantly improve (diastolic) blood pressure.
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Switching from olanzapine to quetiapine or aripiprazole 
and metformin demonstrated the best evidence for glucose 
level reductions, followed by GLP­1 RAs, dietary interventions 
and aripiprazole augmentation. Hemoglobin A1c was reduced 
significantly by both metformin and GLP­1 RAs. Homeostatic 
model assessment of insulin resistance improved significantly 
with metformin and rosiglitazone.
Reduction of triglycerides levels were the largest with topira­
mate, followed by multidisciplinary lifestyle/behavioral inter­
ventions, metformin, aripiprazole augmentation and GLP­1 
RAs. Total cholesterol was reduced by metformin, lifestyle 
interventions and aripiprazole augmentation, while LDL­ 
cholesterol reductions were significant with topiramate, life­
style interventions and GLP­1 RAs. HDL­cholesterol only in­
creased significantly with metformin. Finally, only exercise 
interventions were meta­analyzed as a means to improve exer­
cise capacity, yielding the largest effect size of all interventions 
in this review for any outcome (SMD=1.81), although this was 
based on only one trial.
Taken together, our data offer clinicians some perspective on 
the potential best methods to address specific physical health 
issues in people with schizophrenia. In summary, for weight 
reduction, clinicians should consider individual lifestyle coun­
selling as the top non­pharmacological intervention. There is 
some evidence that exercise interventions can also help reduce 
body weight, although we could only include four trials. Dietary 
interventions also showed promise. Regarding pharmacologi­
cal interventions, clinicians could consider the adjunctive use 
of topiramate, though this should be balanced against the pos­
sible emergence of paresthesia and cognitive adverse effects 
(the latter insufficiently studied). Findings for metformin were 
somewhat heterogeneous, as this medication had a medium ef­
fect on body weight but no effect on body mass index, although 
the latter was likely due to the smaller number of studies exam­
ining this outcome. Metformin may be associated with nausea 
and diarrhea. Further research is required to determine the 
effects of combining these strategies.
With regards to other markers of metabolic health and car­
diovascular risk, there is good evidence that clinicians can use 
metformin for reducing glucose levels, homeostatic model 
assessment of insulin resistance and total cholesterol, while 
there is only a small effect for triglycerides, hemoglobin A1c and 
HDL­cholesterol. For people with schizophrenia on olanzapine, 
switching to aripiprazole or quetiapine also shows medium 
glucose level lowering effects. Of note, only dietary interventions 
were found to significantly improve (diastolic) blood pressure.
Our data should be considered in the light of some limi­
tations. First, although the included meta­analyses were the 
most updated and/or largest for each specific strategy and 
outcome, individual studies published since the last search 
date of included meta­analyses could not be added. Second, 
because of limited data for participant characteristics and in­
terventional designs, conducting meta­regression analyses 
was not possible. Third, while the quality of the methods of the 
meta­analyses was generally good to very good, the content of 
meta­analyzed studies often lacked quality. Fourth, based on 
the AMSTAR­Plus Content scores, publication bias was prob­
lematic for about half of the meta­analyses, potentially overes­
timating the pooled effect sizes. Finally, the preponderance of 
studies with small sample sizes in which only large effects were 
statistically significant presents a challenge.
In conclusion, despite the high risk for physical comorbidi­
ties in people with schizophrenia, and the scandal of their 
premature mortality mainly due to these increased physical 
health risks, the existing evidence for pharmacological and 
non­pharmacological interventions to prevent and treat these 
conditions is still limited. Qualitatively excellent and suffi­
ciently large individual randomized clinical trials are therefore 
essential.
Additionally, the field should move from study­level to pa­
tient­level meta­analyses, as this would provide a more person­
alized picture of treatment effects for individuals, derived from 
adequately powered moderator, mediator and subgroup analy­
ses. Comparing pharmacological and non­pharmacological in­
terventions in the same trial would also be desirable, and there 
is a need for large­scale investigations of combination regimes 
(i.e., using antipsychotic switching and adjunctive prescribing 
alongside lifestyle interventions), as well as preventive inter­
ventions (i.e., those aiming to prevent physical comorbidities, 
prior to their development).
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